Michael Mahler

Chief Scientific Officer
Exagen Inc.
Life Sciences/Biotech Executive

At Exagen Inc., Chief Scientific Officer[TB1] Michael Mahler translates complex immunology into practical diagnostic innovations that improve patient outcomes for autoimmune diseases. Tasked with driving scientific strategy, he focuses on precision medicine in a field where symptoms often overlap and delayed diagnosis can lead to disease progression. Mahler’s extensive background includes contributing to more than 300 peer-reviewed publications and securing numerous patents related to autoantigens and biomarker performance.

In the last 12–24 months, Exagen has continued expanding clinically relevant biomarker access in autoimmune care, including recent launches such as Anti-RA33 and Anti-PAD4 – supporting more nuanced assessment when the differential diagnosis is complex. Beyond his executive duties, he fosters global collaboration through Autoimmunity Insights, a LinkedIn community he created to convene leaders from industry and academia. Mahler’s work bridges the gap between scientific discovery and real-world clinical application, accelerating the development of diagnostic platforms that change the trajectory of care for patients worldwide.